Abstract:

BACKGROUND: Currently, only granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) approved by Food and Drug Administration are used for the mobilization of peripheral blood hemopoietic stem cells and G-CSF alone or in combination with GM-CSF is the predominant mobilization regiments used in the allogeneic setting, but it might cause the donors some adverse events such as bone pain, muscular soreness and fever.
OBJECTIVE: To retrospectively review the clinic results of allogeneic peripheral blood hemopoietic stem cell transplantation (allo-PBSCT) using mobilization with G-CSF and GM-CSF.
METHODS: From January 2004 to October 2009, a total of 51 patients with hematological malignant diseases received allo-PBSCT from human leucocyte antigen-matched sibling donors mobilized with G-CSF and GM-CSF at the Department of Hematology, Henan Provincial People’s Hospital. We analyzed components in the allografts, hematopoietic reconstitution and the incidence of graft versus host diseases (GVHD).
RESULTS AND CONCLUSION: After mobilizing 96 hours, the percentage of CD34⁺ cells in mononuclear cells was (0.97±0.13)% and the percentage of CD34⁺/CD38^- cells in CD34⁺ cells was (37.49±4.03)%. Rapid hematopoietic reconstruction posttransplantation was negatively associated with infused total CD34⁺ and CD34⁺/CD38^- cell number. Incidences of Grades Ⅰ, Ⅱ–Ⅳ acute GVHD were respectively 25.5% and 15.7% of patients. The incidence rates of limited and extensive chronic GVHD were 39.2% and 21.2% separately. These results suggest the combination regimen with GM-CSF and G-CSF appear to have a good effect in the mobilization of peripheral blood stem cells and be sufficient to ensure early hematopoietic reconstitution. The high doses of infused CD34⁺ and CD34⁺CD38^- cells are likely beneficial to the prompt engraftment.